Almstead Neil Gregory 4
4 · PTC THERAPEUTICS, INC. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
PTC Therapeutics (PTCT) CTO Neil Almstead Exercises Options, Sells Shares
What Happened
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (PTCT), exercised a total of 46,774 option shares and sold 46,774 common shares in transactions reported July 6–7, 2026. He exercised 19,687 shares at $38.10 and 27,087 shares at $39.42 (total exercise cost ≈ $1.82M) and sold the resulting shares in multiple open-market trades for total proceeds of ≈ $4.09M (net proceeds before taxes/fees ≈ $2.28M). The exercises and sales were effectively same-day (cashless-style disposition).
Key Details
- Transaction dates: July 6–7, 2026; Form 4 filed July 8, 2026 (appears timely).
- Options exercised: 46,774 shares (19,687 @ $38.10; 27,087 @ $39.42); total exercise cost ≈ $1,817,844.
- Shares sold: 46,774 shares in multiple trades for total proceeds ≈ $4,093,482 (weighted avg ≈ $87.5/share). Trade prices ranged roughly $85.00–$89.75 per footnotes.
- Net cash (proceeds minus exercise cost): roughly $2.28M before taxes and fees.
- Post-transaction holdings: not provided in the summary here — see the full Form 4 for shares owned after these transactions.
- Notable footnotes: some sales were executed pursuant to a written Rule 10b5-1 trading plan (adopted Nov 11, 2025); option grants and vesting tied to a Jan 5, 2023 grant schedule; several sale prices are reported as weighted averages across multiple trade prices. One footnote also notes 162 shares acquired under the issuer’s ESPP for the period ended June 30, 2026.
Context
- These were option exercises followed immediately by open-market sales of the same number of shares — a common cashless exercise/tax-covering pattern rather than an additional market purchase.
- Sales by officers are routine liquidity events and do not, by themselves, prove a change in insider sentiment. Purchases generally carry more direct informational weight than routine option exercises and subsequent sales.
- For full details (exact per-trade prices, post-transaction holdings, and which trades were under the 10b5-1 plan), consult the complete Form 4 filing (Accession No. 0001578850-26-000021).
Insider Transaction Report
Form 4
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2026-07-06$38.10/sh+811$30,899→ 61,110 total - Sale
Common Stock
[F1][F3]2026-07-06$85.28/sh−426$36,329→ 60,684 total - Sale
Common Stock
[F1][F4]2026-07-06$86.34/sh−385$33,241→ 60,299 total - Exercise/Conversion
Common Stock
[F1]2026-07-06$38.10/sh+18,876$719,176→ 79,175 total - Sale
Common Stock
[F1][F5]2026-07-06$85.35/sh−8,786$749,885→ 70,389 total - Sale
Common Stock
[F1][F6]2026-07-06$86.32/sh−10,090$870,969→ 60,299 total - Exercise/Conversion
Common Stock
[F1]2026-07-06$39.42/sh+2,474$97,525→ 62,773 total - Sale
Common Stock
[F1][F7]2026-07-06$87.03/sh−2,474$215,312→ 60,299 total - Exercise/Conversion
Common Stock
[F1]2026-07-07$39.42/sh+24,613$970,244→ 84,912 total - Sale
Common Stock
[F1][F8]2026-07-07$87.17/sh−3,956$344,845→ 80,956 total - Sale
Common Stock
[F1][F9]2026-07-07$89.03/sh−11,369$1,012,182→ 69,587 total - Sale
Common Stock
[F1][F10]2026-07-07$89.44/sh−9,288$830,719→ 60,299 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F11]2026-07-06−811→ 18,876 totalExercise: $38.10Exp: 2032-01-06→ Common Stock (811 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F11]2026-07-06−18,876→ 0 totalExercise: $38.10Exp: 2032-01-06→ Common Stock (18,876 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F12]2026-07-06−2,474→ 33,676 totalExercise: $39.42Exp: 2033-01-04→ Common Stock (2,474 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F12]2026-07-07−24,613→ 9,063 totalExercise: $39.42Exp: 2033-01-04→ Common Stock (24,613 underlying)
Holdings
- 2,899(indirect: By Spouse)
Common Stock
[F2]
Footnotes (12)
- [F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
- [F10]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $89.29 to $89.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F11]Currently exercisable.
- [F12]This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
- [F2]Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.
- [F3]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F6]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.03 to $86.74 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F7]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $87.00 to $87.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F8]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $87.00 to $87.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F9]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $88.29 to $89.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Signature
/s/ Avraham S. Adler, Attorney-in-Fact|2026-07-08